Himalaya Nutravedics India IPO Final Day: GMP ₹0
Well folks, we’ve reached the final stretch for the Himalaya Nutravedics India SME IPO. Today marks Day 3, the closing day, and it’s time to take a good, hard look at where things stand. As the clock ticks down, investors are making their final decisions. Let’s dive into the subscription numbers and the Grey Market Premium (GMP) to get a clearer picture.
| Date | GMP | Est. Listing |
|---|---|---|
| 28 Sep | ₹0 | ₹106 |
Subscription Status
This is where things get a bit… quiet. As of the closing bell on Day 3, the subscription figures for Himalaya Nutravedics India are showing zero across the board: Retail, Non-Institutional Investors (NII), and Qualified Institutional Buyers (QIB). This means absolutely no shares have been subscribed by any category. This is certainly an unusual situation, especially on the closing day of an IPO. Typically, by the final day, we’d expect to see some level of interest, even if it’s modest. The lack of any subscription, particularly from retail investors who usually form a significant chunk of SME IPO interest, is something to ponder. It could indicate a lack of awareness, perhaps a perceived lack of compelling value, or simply that investors are waiting for more concrete signals before committing their capital. The fact that QIBs and NIIs haven’t shown any interest is also noteworthy and could be a sign that institutional players aren’t seeing the immediate upside they look for.
| Category | Subscription | Progress |
|---|---|---|
| Retail | 0.00x | |
| NII / HNI | 0.00x | |
| QIB | 1.00x | |
| Total | 1.00x |
GMP Update
Now, let’s talk about the Grey Market Premium (GMP). For Himalaya Nutravedics India, the GMP has remained stagnant at ₹0. This has been consistent from yesterday and continues today. A GMP of ₹0 essentially means the market is expecting the stock to list at its issue price of ₹106. There’s no premium, and thankfully, no discount either. This lack of any upward price discovery in the grey market aligns with the subdued subscription numbers. It suggests that the market sentiment, as reflected by informal trading, isn’t generating excitement or anticipation for a significant listing gain. While a ₹0 GMP isn’t a red flag in itself, it doesn’t provide the kind of positive buzz that can often drive IPO subscriptions, especially in the SME segment where listing gains can be a major draw for investors.
Should You Apply?
So, the big question: should you have applied for Himalaya Nutravedics India’s IPO? Looking at the data, it’s a tough call. On one hand, the subscription numbers are concerningly low, showing no interest from any investor category. Coupled with a GMP of ₹0, which suggests a flat listing at the issue price of ₹106, there isn’t a strong indication of immediate listing gains. The lot size is 1200 shares, so a flat listing means no profit on the initial investment. However, it also means you won’t be taking on immediate risk of listing losses, assuming the company performs as expected post-listing. For those who believe in the long-term prospects of Himalaya Nutravedics India and its business model, applying at the issue price might still be an option, especially if they are looking to add to their portfolio at a potentially fair valuation. Remember, SEBI advisors always recommend thorough due diligence and understanding the company’s fundamentals before investing. The bottom line is, with zero subscriptions and zero GMP, this IPO presents a very cautious investment opportunity. You’ll need to weigh your personal investment goals and risk appetite very carefully.